Shares in Neuren Pharmaceuticals rallied in morning trade, after ending Wednesday's session as the worst performing ASX 200 ...

The market didn't like what this stock had to say this morning... The post Why did this $1.4 billion ASX 200 healthcare stock ...

Neuren Pharmaceuticals' Rett syndrome treatment, trofinetide, is a step closer to receiving regulatory approval in the ...

Neuren's partner Acadia Pharmaceuticals submits marketing authorisation application in Europe for trofinetide for treatment ...

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Neuren Pharmaceuticals Limited has announced an update on its ongoing share buy-back program, confirming the ...

Neuren Pharmaceuticals Limited (AU:NEU) has released an update. Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Neuren Pharmaceuticals Limited (AU:NEU) has released an update. Pick the best stocks and maximize your portfolio: Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!

Key Insights The projected fair value for Neuren Pharmaceuticals is AU$20.56 based on 2 Stage Free Cash Flow to Equity... Neuren Pharmaceuticals Limited ( ASX:NEU ) shareholders will have a reason ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Neuren Pharmaceuticals Limited has announced the continuation of its on-market buy-back program ...